High-risk, early-stage HER2-positive breast cancer patients receiving adjuvant pertuzumab were younger than patients who did not receive adjuvant pertuzumab (mean age of 48.4 compared to 55.8 years, P < 0.0001) (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.